Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

25.69
-0.3000-1.15%
Volume:892.69K
Turnover:22.88M
Market Cap:4.10B
PE:-62.46
High:25.99
Open:25.63
Low:25.10
Close:25.99
52wk High:26.16
52wk Low:12.00
Shares:159.76M
Float Shares:125.00M
Volume Ratio:0.54
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4113
EPS(LYR):-0.3922
ROE:-38.76%
ROA:-4.12%
PB:28.72
PE(LYR):-65.51

Loading ...

Adaptive Biotechnologies plans separation of MRD, Immune Medicine units

Reuters
·
Jun 16

Adaptive Biotechnologies - Expects to Identify Immune Medicine Separation Path by Year-End 2026

THOMSON REUTERS
·
Jun 16

Adaptive Biotechnologies Announces Plan to Separate Its Mrd and Immune Medicine Businesses

THOMSON REUTERS
·
Jun 16

Adaptive Biotechnologies plans USD 250 million convertible senior notes offering due 2031

Reuters
·
Jun 16

Adaptive Biotechnologies - to Offer $250 Mln Convertible Senior Notes Due 2031

THOMSON REUTERS
·
Jun 16

Adaptive Biotechnologies - Proceeds to Fund Capped Call and Repurchase up to $25 Mln Common Stock

THOMSON REUTERS
·
Jun 16

Adaptive Biotechnologies - Proceeds Expected to Repay Orbimed Purchase Agreement

THOMSON REUTERS
·
Jun 16

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

GlobeNewswire
·
Jun 16

Adaptive Biotechnologies (ADPT) Stock After clonoSEQ Presentations At ASCO And EHA Is 12.6% Undervalued

Simply Wall St.
·
Jun 13

Is Adaptive Biotechnologies (ADPT) Turning clonoSEQ’s MRD Momentum Into a Durable Competitive Moat?

Simply Wall St.
·
Jun 10

Adaptive Biotechnologies shareholders re-elect Hershberg, Owen to board

Reuters
·
Jun 10

Adaptive Biotechnologies Chief People Officer Francis Lo disposes of 39,741 common shares for $695,772.09

Reuters
·
Jun 09

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 11,000 shares for $198,000

Reuters
·
Jun 09

Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology?

Simply Wall St.
·
Jun 01

Adaptive Biotech says clonoSEQ MRD test features in 33 ASCO, EHA presentations

Reuters
·
May 29

Adaptive Biotechnologies Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 13

Morgan Stanley Lowers Price Target on Adaptive Biotechnologies to $18 From $21, Keeps Equalweight Rating

MT Newswires Live
·
May 12

A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong Q1 MRD Growth And Raised Full Year Guidance

Simply Wall St.
·
May 10

Stock Track | Adaptive Biotechnologies Soars 8.85% in Pre-market on Strong Q1 Earnings Beat and Analyst Support

Stock Track
·
May 06

Adaptive Biotechnologies Price Target Maintained With a $22.00/Share by BTIG

Dow Jones
·
May 06